Although rare by definition, the collective impact of rare diseases is anything but insignificant. In the Asia Pacific (APAC) region, home to over half of the world’s population, more than 258 million people are estimated to be living with a rare disease. This staggering figure becomes even more pronounced on a global scale. Yet treatment options remain scarce, creating a pressing issue of healthcare equity. Addressing this challenge requires deeper understanding and urgent action.

Despite having a strong immuno-oncology portfolio, Bristol Myers Squibb (BMS) was looking for ways to fully leverage the rapid expansion of the cancer treatment market in Malaysia. To unlock this potential, BMS partnered with DKSH to provide market expertise and uncover opportunities for sustainable double-digit growth.

Myanmar is a country with rich cultural heritage and a robust economy, yet many communities still face challenges in accessing quality education and essential resources.